# Advanced delivery of natural bioactive compounds for atopic dermatitis: a review of polymeric conjugates and nanocarriers

**Authors:** Jigar Vyas, Nensi Raytthatha, Puja Vyas, Sudarshan Singh, Bhupendra G. Prajapati

PMC · DOI: 10.1007/s13659-025-00585-w · 2026-02-05

## TL;DR

This review explores how natural compounds can be delivered using advanced polymer and nanocarrier systems to treat atopic dermatitis more safely and effectively.

## Contribution

The paper highlights recent advances in polymeric conjugates and nanocarriers for delivering natural bioactives in atopic dermatitis treatment.

## Key findings

- Natural compounds like flavonoids and polyphenols show promise for treating atopic dermatitis.
- Polymeric conjugates and nanocarriers improve the delivery and efficacy of these compounds.
- These systems reduce systemic side effects and enhance skin barrier repair.

## Abstract

Atopic dermatitis (AD) is a persistent, relapsing skin inflammatory disorder characterised by epidermal barrier dysfunction, immune system anomalies, and microbial dysbiosis. Current therapies encompass calcineurin inhibitors, topical corticosteroids, and synthetic drugs such as JAK inhibitors and biologics, which, despite their efficacy, have safety issues and constraints on prolonged use. Recently, natural bioactive compounds namely flavonoids, polyphenols, and terpenoids have garnered interest for their anti-inflammatory, antioxidant, and skin-barrier-repairing characteristics. Recent studies emphasise the incorporation of these bioactive compounds into hydrophilic/hydrophobic polymeric conjugates and nanocarrier systems to promote skin distribution, increase efficacy, and minimise systemic adverse effects. This study encapsulates traditional and innovative medicines, highlights the promise of polymer-conjugated herbal formulations, and examines recent developments in nanotechnology and delivery technologies for AD management. The increasing interest in bioactive ingredient formulations and polymeric nanocarriers indicates a favourable shift towards safer, more effective, and patient-compliant treatment methodologies.

## Linked entities

- **Diseases:** atopic dermatitis (MONDO:0004980)

## Full-text entities

- **Genes:** CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, Il22 (interleukin 22) [NCBI Gene 50929] {aka IL-22, IL-22a, ILTIFa, If2b1, Iltif}, Aqp3 (aquaporin 3) [NCBI Gene 11828] {aka AQP-2}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Cmtm2a (CKLF-like MARVEL transmembrane domain containing 2A) [NCBI Gene 73381] {aka 1700001K04Rik, 1700041N15Rik, 1700063K20Rik, ARR19, C32, CKLF3}, Ivl (involucrin) [NCBI Gene 16447] {aka 1110019C06Rik}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Jak1 (Janus kinase 1) [NCBI Gene 16451] {aka BAP004, C130039L05Rik}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, IL4R (interleukin 4 receptor) [NCBI Gene 3566] {aka CD124, IL-4RA, IL4RA}, Il31 (interleukin 31) [NCBI Gene 76399] {aka 1700013B14Rik}
- **Diseases:** Chronic inflammation (MESH:D007249), bone marrow suppression (MESH:D001855), itch (MESH:D011537), scratch (MESH:D002372), anxiety (MESH:D001007), telangiectasis (MESH:D013684), sleeplessness (MESH:D007319), contact dermatitis (MESH:D003877), allergic conditions (MESH:D004342), dermatoses (MESH:D012871), pain (MESH:D010146), scabies (MESH:D012532), sleep disorder (MESH:D012893), microbial dysbiosis (MESH:D064806), edema (MESH:D004487), hyperkeratosis (MESH:D017488), Immune (MESH:D007154), ear swelling (MESH:D004427), trauma (MESH:D014947), dermatological diseases (MESH:D000168), oedema (MESH:C536897), AD (MESH:D003876), psoriasis (MESH:D011565), eczematous (MESH:D017443), water loss (MESH:D000069578), inflammatory cytokines (MESH:D000080424), erythroderma (MESH:D003873), Eczema (MESH:D004485), lichen planus (MESH:D008010), skin and eye disorders (MESH:D005128), skin atrophy (MESH:D001284), dryness (MESH:D014987), neurogenic inflammation (MESH:D020078), toxicity (MESH:D064420), malignancy (MESH:D009369), perioral dermatitis (MESH:D019557), acidosis (MESH:D000138), pigmentation (MESH:D010859), immune dysregulation (OMIM:614878), hypertension (MESH:D006973), irritation (MESH:D001523), thrombosis (MESH:D013927), epidermal hyperplasia (MESH:D006965), remodelling (MESH:D020257), conjunctivitis (MESH:D003231), pruritic lesions (MESH:C535817), erythema (MESH:D004890), infected (MESH:D007239), Dermatitis (MESH:D003872), insect bites (MESH:D007299), skin inflammatory disorder (MESH:D012868), cutaneous T cell lymphoma (MESH:D016410)
- **Chemicals:** gallic acid (MESH:D005707), CS-TPP (MESH:C000623170), methylene blue (MESH:D008751), hydrogen (MESH:D006859), MnO2 (MESH:C016552), abrocitinib (MESH:C000634427), LPS (MESH:D008070), water (MESH:D014867), rosmarinic acid (MESH:C041376), methylcellulose (MESH:D008747), ruxolitinib (MESH:C540383), dupilumab (MESH:C582203), poly-(I:C) (MESH:D011070), clobetasol propionate (MESH:D002990), eicosanoid (MESH:D015777), chrysin (MESH:C043561), EGCG (MESH:C045651), diphenhydramine (MESH:D004155), mometasone (MESH:D000068656), flavonoid (MESH:D005419), hydroxyethyl cellulose (MESH:C002283), hydroxyzine (MESH:D006919), aloe-emodin (MESH:C518327), HA (MESH:D006820), resveratrol (MESH:D000077185), haematoxylin (MESH:D006416), berberine (MESH:D001599), methotrexate (MESH:D008727), curcumin (MESH:D003474), Cyclosporine (MESH:D016572), azathioprine (MESH:D001379), terpenoids (MESH:D013729), retinene (MESH:D012172), chlorogenic acid (MESH:D002726), eosin (MESH:D004801), pimecrolimus (MESH:C117268), naringenin (MESH:C005273), H&amp;E (MESH:D006371), carnosic acid (MESH:C018381), steroid (MESH:D013256), phenolic acids (MESH:C017616), essential oils (MESH:D009822), polydimethylsiloxane (MESH:C013830), vitamin A (MESH:D014801), 2,4-dinitrochlorobenzene (MESH:D004137), azadirachtin (MESH:C010329), quercetin (MESH:D011794), prostaglandin D2 (MESH:D015230), ursolic acid (MESH:C005466), Polymer (MESH:D011108), aloin (MESH:C006457), poly (vinyl alcohol) (MESH:D011142), triterpenes (MESH:D014315), nimbidin (MESH:C008620), Eudragit L100 (MESH:C038300), toluidine (MESH:D014052), dexamethasone (MESH:D003907), CUR (-), nitric oxide (MESH:D009569), Kaempferol (MESH:C006552)
- **Species:** Coptis chinensis (species) [taxon 261450], Aloe vera (acibar, species) [taxon 34199], Fumaria parviflora (species) [taxon 1464625], Homo sapiens (human, species) [taxon 9606], Fumaria officinalis (common fumitory, species) [taxon 200993], Mus musculus (house mouse, species) [taxon 10090], Azadirachta indica (Indian-lilac, species) [taxon 124943], Atractylodes lancea (species) [taxon 41486], Silybum marianum (blessed milkthistle, species) [taxon 92921], Calendula officinalis (common marigold, species) [taxon 41496], Salvia rosmarinus (rosemary, species) [taxon 39367], Angelica sinensis (Chinese angelica, species) [taxon 165353], Borago officinalis (species) [taxon 13363], Echinacea (genus) [taxon 53747], Vitellaria paradoxa (karite-nu, species) [taxon 292385], Staphylococcus aureus (species) [taxon 1280], Arctium lappa (great burdock, species) [taxon 4217], Curcuma longa (turmeric, species) [taxon 136217], Xanthoceras sorbifolium (yellow-horn, species) [taxon 99658], Corallina officinalis (species) [taxon 35170], Matricaria chamomilla var. recutita (German chamomile, varietas) [taxon 127986], Lonicera japonica (Japanese honeysuckle, species) [taxon 105884], Paeonia suffruticosa (moutan peony, species) [taxon 45171]
- **Cell lines:** NC/Nga — Homo sapiens (Human), Transformed cell line (CVCL_1874), HaCaT — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0038), HMC-1 — Homo sapiens (Human), Mast cell leukemia, Cancer cell line (CVCL_0003)

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12873061/full.md

---
Source: https://tomesphere.com/paper/PMC12873061